Genomic Health, Inc. (NASDAQ:GHDX) Expected to Post Earnings of $0.38 Per Share

Analysts expect Genomic Health, Inc. (NASDAQ:GHDX) to post $0.38 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Genomic Health’s earnings, with estimates ranging from $0.34 to $0.43. Genomic Health posted earnings of $0.35 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 8.6%. The firm is expected to announce its next earnings results on Tuesday, November 5th.

On average, analysts expect that Genomic Health will report full year earnings of $1.50 per share for the current fiscal year, with EPS estimates ranging from $1.47 to $1.56. For the next fiscal year, analysts forecast that the firm will report earnings of $1.67 per share, with EPS estimates ranging from $1.47 to $1.91. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Genomic Health.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Monday, July 29th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.35 by $0.07. The firm had revenue of $114.14 million during the quarter, compared to analysts’ expectations of $110.78 million. Genomic Health had a net margin of 11.69% and a return on equity of 19.51%. The company’s revenue for the quarter was up 19.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.23 earnings per share.



GHDX has been the subject of a number of analyst reports. Canaccord Genuity cut shares of Genomic Health from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $77.00 to $72.00 in a research note on Tuesday, July 30th. Needham & Company LLC cut shares of Genomic Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 30th. Barclays raised shares of Genomic Health from an “underweight” rating to an “equal weight” rating and increased their price objective for the stock from $45.00 to $72.00 in a research note on Tuesday, July 30th. ValuEngine raised shares of Genomic Health from a “hold” rating to a “buy” rating in a research note on Saturday, July 27th. Finally, Zacks Investment Research raised shares of Genomic Health from a “hold” rating to a “buy” rating and set a $77.00 price objective for the company in a research note on Wednesday, July 31st. Nine equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $69.86.

In related news, CEO Kimberly J. Popovits sold 25,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $73.85, for a total transaction of $1,846,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $51.46, for a total transaction of $257,300.00. The disclosure for this sale can be found here. Insiders have sold 290,601 shares of company stock valued at $18,833,446 over the last ninety days. 31.30% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. lifted its position in Genomic Health by 166.0% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 493 shares during the last quarter. Manchester Capital Management LLC bought a new position in Genomic Health during the first quarter valued at $56,000. Pearl River Capital LLC bought a new position in Genomic Health during the first quarter valued at $70,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Genomic Health by 29.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,923 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 441 shares during the last quarter. Finally, Amalgamated Bank bought a new position in Genomic Health during the fourth quarter valued at $203,000. 95.63% of the stock is owned by institutional investors.

Shares of NASDAQ GHDX traded down $0.30 during midday trading on Wednesday, reaching $74.60. The stock had a trading volume of 31,225 shares, compared to its average volume of 580,696. The business’s 50-day simple moving average is $63.20. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.74 and a quick ratio of 5.74. The company has a market cap of $2.74 billion, a P/E ratio of 71.25 and a beta of 1.06. Genomic Health has a 12-month low of $50.77 and a 12-month high of $92.18.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

See Also: How is a Moving Average Calculated?

Get a free copy of the Zacks research report on Genomic Health (GHDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.